Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
10 févr. 2014 07h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...
Melinta Therapeutics Initiates Phase 3 Registration Study of Delafloxacin in Individuals with Uncomplicated Gonorrhea
09 janv. 2014 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced the initiation of a Phase 3 trial of delafloxacin,
a novel investigational fluoroquinolone, for the...
Melinta Therapeutics to Present at J.P. Morgan Healthcare Conference
09 janv. 2014 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be providing a corporate and clinical update...
Melinta Therapeutics Bolsters Executive Team with Appointment of Paul Estrem as Chief Financial Officer
02 déc. 2013 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Paul Estrem to the role of chief
financial officer. Mr. Estrem brings more than 20 years...
Melinta Therapeutics Prepares for Late-Stage Product Launches with Appointment of Sue Cammarata, M.D. as Chief Medical Officer
19 nov. 2013 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Sue
Cammarata, M.D. as chief medical officer. In this role, Dr.
Cammarata will be...
Melinta Therapeutics Expands Leadership Team with Appointment of Lyn Baranowski as SVP of Corporate Development and Strategy
07 oct. 2013 10h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Lyn
Baranowski as senior vice president, corporate development and
strategy. In this...
Melinta Therapeutics Announces Strategic Realignment and New Corporate Identity Based on Strong Scientific Foundation of Rib-X Pharmaceuticals
07 oct. 2013 09h51 HE
|
Melinta Therapeutics
NEW HAVEN, Conn. & NEW YORK, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc., formerly Rib-X Pharmaceuticals,
today announced the launch a new corporate identity, an...